Transcatheter aortic valve implantation – what do we know in 2020

Česká verzia

Authors: Petr Toušek ¹; Viktor Kočka ¹; Petr Mašek ²
Authors place of work: III. interní – kardiologická klinika 3. LF UK a FN Královské Vinohrady Praha ¹; Medtronic Czechia, s. r. o. (partner v projektu INTERCARDIS) ²
Published in the journal: Vnitř Lék 2020; 66(5): 282-286
Category:

Summary

stenosis is the most common acquired valve disease in adults and the prevalence of this disease is increasing with the aging population. Transcatheter aortic valve implantation (TAVI) became fully established method for treating this disease. The aim of this review is to present the current view of the performance technique, to summarize the data on the outcome of patients from recently published randomized studies and registries and to simply describe patient care after the procedure.

Keywords:

aortic stenosis – patient´s outcome – transcatheter implantation

Zdroje

1. Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J 2018; 39: 2635–2642.

2. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013; 62: 1002–1012.

3. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106: 3006–3008.

4. Cahill TJ, Chen M, Hayashida K, et al. Transcatheter aortic valve implantation: current status and future perspectives. Eur Heart J 2018; 39: 2625–2634.

5. Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of balloon-expandable vs self‑ -expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA 2014; 311: 1503–1514.

6. Adams DH, Popma JJ, Reardon MJ et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790–1798.

7. Gerckens U, Tamburino C, Bleiziffer S et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J 2017; 38: 2729–2738.

8. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686–1695.

9. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016; 374: 1609–1620.

10. Wendler O, Schymik G, Treede H, et al. SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J 2017; 38: 2717–2726.

11. Manoharan G, Van Mieghem NM, Windecker S et al. 1-Year Outcomes With the Evolut R Self-Expanding Transcatheter Aortic Valve: From the International FORWARD Study. JACC Cardiovasc Interv 2018; 11: 2326–2334.

12. Attizzani GF, Patel SM, Dangas GD, et al. Comparison of Local Versus General Anesthesia Following Transfemoral Transcatheter Self-Expanding Aortic Valve Implantation (from the Transcatheter Valve Therapeutics Registry). Am J Cardiol 2019; 123: 419–425.

13. Biancari F, Rosato S, D’Errigo P, et al. Immediate and Intermediate Outcome After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement. Am J Cardiol 2016; 117: 245–251.

14. Cocchieri R, Petzina R, Romano M, et al. Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTE. Eur J Cardiothorac Surg 2019; 55: 737–743

15. Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv 2019; 12: 459–469.

16. Walther T, Hamm CW, Schuler G, et al. Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry. J Am Coll Cardiol 2015; 65: 2173–2180.

17. Ludman PF. UK TAVI registry. Heart 2019; 105: (Suppl. 2): s2–s5.

18. Gaede L, Blumenstein J, Liebetrau C, et al. Outcome after transvascular transcatheter aortic valve implantation in 2016. Eur Heart J 2018; 39: 667–675.

19. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015; 385: 2477–2484.

20. Chakos A, Wilson-Smith A, Arora S, et al. Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond. Ann Cardiothorac Surg 2017; 6: 432–443.

21. Gleason TG, Reardon MD, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. J Am Coll Cardiol 2018; 72: 2687–2696.

22. Thyregod HGH, Ihlemann N, Jorgensen TH, et al. Five-Year Clinical and Echocardiographic Outcomes from the Nordic Aortic Valve Intervention (NOTION) Randomized Clinical Trial in Lower Surgical Risk Patients. Circulation 2019. E pub ahead of print.

23. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–2791.

24. Deeb GM, Chetcuti SJ, Reardon MJ, et al. 1-Year Results in Patients Undergoing Transcatheter Aortic Valve Replacement With Failed Surgical Bioprostheses. JACC Cardiovasc Interv 2017; 10: 1034–1044.

25. Webb JG, Mack MJ, White JM, et al. Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry. J Am Coll Cardiol 2017; 69: 2253–2262.

26. Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J 2019; 40: 441–451.

27. Sondergaard L, Ihlemann N, Capodanno D, et al., Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll Cardiol 2019; 73: 546–553.

28. Sulzenko J, Tousek P, Kocka V, et al. Transcatheter aortic valve implantation: long-term clinical outcome and valve durability. Expert Rev Med Devices 2015; 12: 529–535.

29. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187–2198.

30. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376: 1321–1331.

31. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020 Apr 30; 382(18): 1696–1707.